Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer

Though palbociclib, a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor has been approved for treating breast cancer, two major clinical challenges remain: (i) Triple-negative breast cancer (TNBC) appears to be more resistant to palbociclib, and (ii) Palbociclib-induced senescence-associated secre...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xianzhe, Shi, Wei, Wang, Xumei, Lu, Jin-Jian, He, Ping, Zhang, Hongjie, Chen, Xiuping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522654/
https://www.ncbi.nlm.nih.gov/pubmed/37752122
http://dx.doi.org/10.1038/s41420-023-01658-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522654/
https://www.ncbi.nlm.nih.gov/pubmed/37752122
http://dx.doi.org/10.1038/s41420-023-01658-w

Ejemplares similares